Model Medicines to Participate in the Berenberg Discover AI Seminar 2022
Dr. Daniel Haders, founder and CEO of Model Medicines will be participating in this year’s Berenberg Discover AI Seminar 2022, speaking to the recent acceptance into NIH’s APP, their AI-drug discovery platform and subsequent pipeline, specifically the potential of drug candidate MDL-001. Joining Model Medicines in this event include: AbCellera, Absci, Atomwise, Creyon Bio, Enveda Biosciences, Iktos, Notable Labs, Peptilogics, Recursion, and Simulations Plus.
Recently, Model Medicines MDL-001 compound announced preclinical data demonstrating protection against the primary symptomatic endpoint of COVID-19 and reduction in the viral load of SARS CoV-2 in lungs.
Data surrounding MDL-001 will be the subject of a manuscript being developed in collaboration with research partners, Arnab Chatterjee, PhD, at California Institute for Biomedical Research (Calibr), Scripps Research, as well as Adolfo Garcia-Sastre, PhD, and Kris White, PhD, at the Global Health and Emerging Pathogens Institute, Icahn Mount Sinai School of Medicine.
LA JOLLA, CA., April 25, 2022 -- Model Medicines, the pharmatech company working to transform the drug discovery and development industry and accelerate the creation of life-changing drugs using artificial intelligence (AI) and machine learning (ML), today announced that the company will participate in the Berenberg Discover AI Seminar 2022. This announcement follows recent positive data the company recently released surrounding its Oral Anti-COVID-19 Drug Candidate MDL-001 and their acceptance into the National Institute of Health's (NIH) Antiviral Program for Pandemics (APP).
In late 2021, Model Medicines reported data demonstrating that once daily, oral dosing of MDL-001 protected against the primary symptomatic endpoint (weight-loss) of COVID-19. Then, early this year, the Company announced preclinical results demonstrating once daily, oral dosing of MDL-001 significantly reduces the viral load of SARS-CoV-2 (the virus that causes COVID-19) in the lungs of an established mouse-adapted animal model of SARS-CoV-2 infection. In combination, these results place MDL-001 in an exclusive group of drug candidates that have been reported to demonstrate both significant relief of the symptoms of COVID-19 and significant reduction of viral load in the lungs.
Model Medicines discovered and developed MDL-001, a potent, orally available, direct-acting antiviral agent with an extended half-life, which makes it conducive for simplified patient dosing. The drug has previously been evaluated in Phase I clinical studies evaluating safety and tolerability in a separate indication, and no concerns were noted. Together, these characteristics make MDL-001 an attractive candidate for the next generation of COVID-19 therapies.
Dr. Daniel Haders, founder and CEO of Model Medicines will be participating in this year’s Berenberg Discover AI Seminar 2022, presenting data will be the subject of a manuscript being developed in collaboration with research partners, Arnab Chatterjee, PhD, at California Institute for Biomedical Research (Calibr), Scripps Research, as well as Adolfo Garcia-Sastre, PhD, and Kris White, PhD, at the Global Health and Emerging Pathogens Institute, Icahn Mount Sinai School of Medicine.
ABOUT BERENGERG
Founded in 1590, Berenberg is one of Europe’s leading privately owned banks today with its Wealth and Asset Management, Investment Bank and Corporate Banking divisions. Not only are they Germany’s oldest private bank, they are also one of the most dynamic banks in Europe. They combine over 430 years of experience with a consistent focus on the future.
They use their expertise and innovative solutions for their customers worldwide. Their scale and reach allow them to combine their skills from around the Group to deliver the advice and access to financial markets their clients require.
ABOUT THE MDL-001 DEVELOPMENT PROGRAM
MDL-001 is an oral, direct-acting antiviral agent that is currently undergoing IND (Investigational New Drug) enabling preclinical evaluation as a treatment for patients with COVID-19 in collaboration with partners including Calibr Scripps Research, the Global Health and Emerging Pathogens Institute, Icahn Mount Sinai School of Medicine and the Division of Microbiology and Infectious Diseases (DMID) at the National Institute of Allergy and Infectious Disease (NIAID) and National Institutes of Health (NIH) as part of the Antiviral Program for Pandemics (APP). Model Medicine recently submitted a pre-IND briefing package to the FDA (Food and Drug Administration) for review.
ABOUT MODEL MEDICINES
Model Medicines is an artificial intelligence and machine learning Drug Discovery company that reduces the time to bring a drug to market by 10+ years and the cost to bring a drug to market by $1B+. Model Medicines is transforming drug discovery by leveraging the historical compendium of drug development data, a drug and disease agnostic discovery platform, and unbiased AI to create Phase II/III ready drug candidates in months rather than years. The company has developed a robust pipeline of patent-pending therapeutics for oncology, infectious diseases, gastric disorders, neurological disorders, and weight disorders. The company is based in La Jolla, CA.
